MAPT and breast cancer: We also performed a validation analysis in a third independent cohort from Hispanic luminal B breast cancer patients (Figure 7B), in which we corroborated the overexpression of MAPT-IT and GATA3-AS1 in NAC-resistance breast cancer patients, which are lncRNAs that have been previously identified in fresh frozen tumor samples from breast cancer Hispanic luminal B patients [27].